Halle/Saale, December 10, 2008 — Probiodrug AG (Probiodrug), a developer of small molecule inhibitors for the treatment of inflammatory and neurodegenerative diseases, announced today that the […]
Attenuation of Alzheimer’s disease-like pathology by inhibition of glutaminyl cyclase catalyzed pyroglutamate Aβ formation in transgenic animals Halle/Saale, November 15, 2008 — Probiodrug AG (Probiodrug), a […]
Halle/Saale, September 29th, 2008, 08:00 Uhr MESZ — Probiodrug AG (Probiodrug), a developer of small molecule inhibitors for the treatment of inflammatory and neurodegenerative diseases, today […]
Halle/Saale, 29. September 2008, 08:00 Uhr MESZ — Die Probiodrug AG, ein biopharmazeutisches Unternehmen mit Schwerpunkt auf der Entwicklung von niedermolekularen Inhibitoren im Bereich entzündlicher und […]
Update on Novel QC inhibitors at the American Chemical Society 236th National Meeting, 2008 Halle/Saale // Probiodrug AG (Probiodrug), a developer of small molecule inhibitors for […]
Halle (Saale) // Probiodrug AG (Probiodrug), a developer of small molecule inhibitors for the treatment of inflammatory and neurodegenerative diseases, today announced that Prof Dr Harald […]
QC inhibition to be discussed at Alzheimer’s Association International Conference on Alzheimer’s Disease (ICAD) 2008 Halle (Saale) // Probiodrug AG (Probiodrug), a developer of small molecule […]
Halle (Saale) // Probiodrug AG (Probiodrug), a developer of small molecule inhibitors for the treatment of inflammatory and neurodegenerative diseases, announced today that the company has […]
Halle (Saale), Germany // Probiodrug AG, a developer of small molecule inhibitors for the treatment of inflammatory and neurodegenerative diseases, announced today that the United States […]